BRNS Key Statistics, Chart & Performance
The current stock price of BRNS is 0.7106 USD. In the past month the price decreased by -44.09%. In the past year, price decreased by -27.92%.
BRNS Latest News, Press Relases and Analysis
BRNS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About BRNS
Company Profile
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire. The company went IPO on 2021-04-30. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. The company is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The firm's pipeline also includes VTP-850, VTP-500 and VTP-400.
Company Info
BARINTHUS BIOTHERAPEUTICS PL
Unit 6-10, Zeus Building, Rutherford Avenue, Harwell
Didcot OXFORDSHIRE GB
Employees: 130
Phone: 441865818808
BARINTHUS BIOTHERAPEUTICS PL / BRNS FAQ
Can you describe the business of BARINTHUS BIOTHERAPEUTICS PL?
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire. The company went IPO on 2021-04-30. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. The company is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The firm's pipeline also includes VTP-850, VTP-500 and VTP-400.
Can you provide the latest stock price for BARINTHUS BIOTHERAPEUTICS PL?
The current stock price of BRNS is 0.7106 USD. The price decreased by -0.62% in the last trading session.
Does BARINTHUS BIOTHERAPEUTICS PL pay dividends?
BRNS does not pay a dividend.
What is the ChartMill technical and fundamental rating of BRNS stock?
BRNS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in BARINTHUS BIOTHERAPEUTICS PL be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BRNS.
Can you provide the upcoming earnings date for BARINTHUS BIOTHERAPEUTICS PL?
BARINTHUS BIOTHERAPEUTICS PL (BRNS) will report earnings on 2026-03-18, after the market close.
Can you provide the short interest for BRNS stock?
The outstanding short interest for BARINTHUS BIOTHERAPEUTICS PL (BRNS) is 0.12% of its float.
BRNS Technical Analysis
BRNS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BRNS. No worries on liquidiy or solvency for BRNS as it has an excellent financial health rating, but there are worries on the profitability.
BRNS Financial Highlights
Over the last trailing twelve months BRNS reported a non-GAAP Earnings per Share(EPS) of -1.76. The EPS decreased by -18.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.93% | ||
| ROE | -72.31% | ||
| Debt/Equity | 0 |
BRNS Forecast & Estimates
8 analysts have analysed BRNS and the average price target is 5.1 USD. This implies a price increase of 617.7% is expected in the next year compared to the current price of 0.7106.
For the next year, analysts expect an EPS growth of -22.4% and a revenue growth -100% for BRNS